Corbus 15min chart triggers KDJ Golden Cross, bullish Marubozu formation observed.
ByAinvest
Monday, Sep 29, 2025 3:26 pm ET1min read
CRBP--
The trading session was marked by a decline in the NASDAQ Composite Index (COMP) and the Dow Jones Industrial Average (DJIA), with the former falling 0.50% to 22,384.70 and the latter dropping 0.38% to 45,947.32. Despite this, CRBP managed to snap its losing streak and even exceeded its 50-day average trading volume of 123,286, with a volume of 134,222 shares traded [1].
The 15-minute chart for CRBP has shown a significant technical indicator shift, triggering a golden cross as indicated by the KDJ indicator, alongside a bullish marubozu pattern observed on September 29, 2022, at 15:15. This suggests a potential upward trajectory for the stock, with the market currently favoring buyers .
Corbus Pharmaceuticals Holdings Inc. has also outperformed some of its competitors on the same day. Vanda Pharmaceuticals Inc. (VNDA) fell 1.43% to $4.83, Fortress Biotech Inc. (FBIO) rose 1.63% to $3.75, and Viking Therapeutics Inc. (VKTX) fell 5.78% to $25.09 [1].
Investors should monitor the ongoing momentum and technical indicators to gauge the stock's potential for further price appreciation. The current bullish signals and market conditions may suggest that CRBP could continue its upward trend.
The 15-minute chart for Corbus has triggered a golden cross, as indicated by the KDJ indicator, alongside a bullish marubozu pattern observed on September 29, 2022, at 15:15. This indicates a shift in momentum towards an upward trajectory, suggesting that the stock price has the potential to continue increasing. The control of the market is currently held by buyers, and it is likely that the bullish momentum will persist.
Corbus Pharmaceuticals Holdings Inc. (CRBP) experienced a notable upturn in its stock price on September 29, 2022, despite a broader market downturn. The stock advanced by 5.38% to $12.14, outperforming some of its competitors. This rebound comes after a two-day losing streak, with the stock closing 47.96% short of its 52-week high of $23.33 [1].The trading session was marked by a decline in the NASDAQ Composite Index (COMP) and the Dow Jones Industrial Average (DJIA), with the former falling 0.50% to 22,384.70 and the latter dropping 0.38% to 45,947.32. Despite this, CRBP managed to snap its losing streak and even exceeded its 50-day average trading volume of 123,286, with a volume of 134,222 shares traded [1].
The 15-minute chart for CRBP has shown a significant technical indicator shift, triggering a golden cross as indicated by the KDJ indicator, alongside a bullish marubozu pattern observed on September 29, 2022, at 15:15. This suggests a potential upward trajectory for the stock, with the market currently favoring buyers .
Corbus Pharmaceuticals Holdings Inc. has also outperformed some of its competitors on the same day. Vanda Pharmaceuticals Inc. (VNDA) fell 1.43% to $4.83, Fortress Biotech Inc. (FBIO) rose 1.63% to $3.75, and Viking Therapeutics Inc. (VKTX) fell 5.78% to $25.09 [1].
Investors should monitor the ongoing momentum and technical indicators to gauge the stock's potential for further price appreciation. The current bullish signals and market conditions may suggest that CRBP could continue its upward trend.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet